Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Eton Pharmaceuticals, with four buy ratings and two holds. The average 12-month price target is $67.50, with several firms recently raising their targets.
• Eton reported quarterly EPS of $0.43, beating expectations of $0.19, while revenue of $37.59 million exceeded the $27.11 million consensus estimate.
• Insiders sold a combined 75,000 shares in recent transactions, while company insiders still own 16.49% of the stock and institutional investors hold 27.86%.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) has received an average rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $67.50.

ETON has been the subject of a number of research analyst reports. Canaccord Genuity Group lifted their price target on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a "buy" rating in a research note on Friday, August 14th. B. Riley Financial reiterated a "buy" rating and set a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Zacks Research raised shares of Eton Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Monday, August 24th. Weiss Ratings upgraded shares of Eton Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a research note on Tuesday. Finally, Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, July 28th.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON opened at $59.49 on Friday. Eton Pharmaceuticals has a fifty-two week low of $14.27 and a fifty-two week high of $66.37. The business has a 50 day moving average price of $53.37 and a two-hundred day moving average price of $37.47. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. The firm has a market cap of $1.70 billion, a PE ratio of 156.55 and a beta of 0.90.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.24. The company had revenue of $37.59 million for the quarter, compared to the consensus estimate of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. Sell-side analysts expect that Eton Pharmaceuticals will post 1.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider David Krempa sold 25,000 shares of Eton Pharmaceuticals stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $65.07, for a total value of $1,626,750.00. Following the completion of the transaction, the insider owned 37,025 shares in the company, valued at approximately $2,409,216.75. This trade represents a 40.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul V. Maier sold 50,000 shares of the business's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $59.07, for a total value of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares of the company's stock, valued at $3,529,137.15. This trade represents a 45.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 16.49% of the company's stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Toth Financial Advisory Corp acquired a new stake in shares of Eton Pharmaceuticals during the second quarter worth $43,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Eton Pharmaceuticals in the 4th quarter valued at about $50,000. Persistent Asset Partners Ltd acquired a new position in shares of Eton Pharmaceuticals in the 2nd quarter valued at about $90,000. State of Wyoming bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $107,000. Finally, Quantbot Technologies LP bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $165,000. Institutional investors and hedge funds own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for underserved patient populations, with an emphasis on pediatric, rare disease and other difficult-to-treat conditions. The company generally pursues products with established clinical or regulatory pathways and works to bring them to market through its own commercial operations or strategic partnerships.

Eton's marketed portfolio includes Eprontia, an oral solution formulation of topiramate used in the treatment of certain seizure disorders; Biorphen, an injectable phenylephrine product used to treat clinically important low blood pressure; and Alkindi Sprinkle, a hydrocortisone granule product for replacement therapy in children with adrenal insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.